With the very-recent FDA approval of Amgen's Prolia®, this dropout rate (or "switch-over" rate, if one prefers) is very likely to rise in the U.S. Note that 61 percent of patients go off of Fosamax® (or its generic equivalent, alendronate) within a year, according to a just released SDI analysis. This really is the hard winter's freeze setting in, on Fosamax: . . . .Currently, alendronate, sometimes filled as Fosamax but more frequently as the generic equivalent, is the most popular treatment... Continuar leyendo